HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Galectin Therapeutics (NASDAQ:GALT) and maintained a price target of $11.
August 16, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Galectin Therapeutics and maintained a price target of $11.
The reiteration of a Buy rating and the maintenance of a price target at $11 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100